» Articles » PMID: 10224296

Neuronal Messengers and Peptide Receptors in the Human Sphenopalatine and Otic Ganglia

Overview
Journal Brain Res
Specialty Neurology
Date 1999 May 4
PMID 10224296
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

A majority of the parasympathetic nerve fibers to cranial structures derive from the sphenopalatine and otic ganglia. In particular, blood vessels are invested with a rich supply of dilator fibers of parasympathetic origin. In the present study, we have examined the occurrence of noncholinergic neuromessengers and neuropeptide receptors in the human sphenopalatine and otic ganglia. Vasoactive intestinal peptide (VIP)-immunoreactive (ir) nerve cell bodies occurred in high numbers in the sphenopalatine and otic ganglia. Likewise, high numbers of NOS- and PACAP-containing nerve cell bodies were seen in both ganglia. Autofluorescent lipofuscin, characteristic of adult human nervous tissue, was present within many nerve cell bodies in both ganglia. Receptor mRNA was studied with reverse transcriptase-polymerase chain reaction (RT-PCR). Total RNA from the sphenopalatine and otic ganglia was successfully extracted. By using appropriate sense and antisense primers, oligonucleotides were designed from the human sequences derived from GenBank, corresponding to human NPY Y1, CGRP1 and VIP1 receptors. In the sphenopalatine ganglion, we revealed the presence of mRNA for the human NPY Y1 and VIP1 receptors but not the CGRP1 receptor. The otic ganglion was found to react positively only for primers to mRNA for VIP1 but not for CGRP1 or NPY Y1 receptors.

Citing Articles

Hallmarks of primary headache: part 1 - migraine.

Raggi A, Leonardi M, Arruda M, Caponnetto V, Castaldo M, Coppola G J Headache Pain. 2024; 25(1):189.

PMID: 39482575 PMC: 11529271. DOI: 10.1186/s10194-024-01889-x.


Pituitary adenylate cyclase-activating polypeptide signalling as a therapeutic target in migraine.

Ashina H, Christensen R, Hay D, Pradhan A, Hoffmann J, Reglodi D Nat Rev Neurol. 2024; 20(11):660-670.

PMID: 39256637 DOI: 10.1038/s41582-024-01011-4.


Pituitary cyclase-activating polypeptide targeted treatments for the treatment of primary headache disorders.

Karsan N, Edvinsson L, Vecsei L, Goadsby P Ann Clin Transl Neurol. 2024; 11(7):1654-1668.

PMID: 38887982 PMC: 11251486. DOI: 10.1002/acn3.52119.


Intervening in the Premonitory Phase to Prevent Migraine: Prospects for Pharmacotherapy.

Karsan N, Goadsby P CNS Drugs. 2024; 38(7):533-546.

PMID: 38822165 DOI: 10.1007/s40263-024-01091-2.


Shared and independent roles of CGRP and PACAP in migraine pathophysiology.

Kuburas A, Russo A J Headache Pain. 2023; 24(1):34.

PMID: 37009867 PMC: 10069045. DOI: 10.1186/s10194-023-01569-2.